Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASP3082 + leucovorin + fluorouracil + irinotecan + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
ASP3082 + leucovorin + fluorouracil + irinotecan + oxaliplatin is an investigational combination regimen being evaluated for the treatment of advanced solid tumors harboring the KRAS G12D mutation, notably in pancreatic cancer. ASP3082 is a novel small-molecule proteolysis-targeting chimeric (PROTAC) degrader designed to selectively bind and degrade the mutant KRAS G12D protein via recruitment of E3 ubiquitin ligases, leading to growth inhibition of KRAS G12D-mutated cancer cells[4]. The regimen combines ASP3082 with the standard FOLFIRINOX chemotherapy protocol (leucovorin, fluorouracil, irinotecan, oxaliplatin) to potentially enhance antitumor response. The primary developer of ASP3082 is Astellas Pharma.
- Other names
- FOLFIRINOX + ASP3082
02
Targets
TS (Thymidylate synthase)DNAVHL (Von Hippel–Lindau tumor suppressor protein)KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on ASP3082 + leucovorin + fluorouracil + irinotecan + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASP3082 + leucovorin + fluorouracil + irinotecan + oxaliplatin.